欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

未开盘 08-31 16:08:48

5.170

-0.130

-2.45%

最高5.210	最低5.130	成交量14.90万
今开5.160	昨收5.300	日振幅1.51%
总市值42.14亿	流通市值42.14亿	总股本8.15亿
成交额77.03万	换手率0.02%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":5.17,"timestamp":1788163728002,"preClose":5.3,"halted":0,"volume":149000,"delay":0,"changeRate":-0.024528301886792434,"floatShares":815000000,"shares":815000000,"eps":-0.2333312429449392,"marketStatus":"未开盘","change":-0.13,"latestTime":"08-31 16:08:48","open":5.16,"high":5.21,"low":5.13,"amount":770300,"amplitude":0.015094,"askPrice":5.17,"askSize":21000,"bidPrice":5.13,"bidSize":17000,"shortable":3,"etf":0,"ttmEps":-0.17976422284585478,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":5.3,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.318717,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2663006583","title":"歌礼制药-B(01672)发布中期业绩 股东应占亏损3.2亿元 同比增加263.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006583","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663006583?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:24","pubTimestamp":1788182651,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。人体数据表明，ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂，预计将于2026年第四季度向FDA递交IND。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","BK1191","BK1515","BK1161","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150796215","title":"欧康维视生物-B（01477）OT-202在华III期试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1150796215","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150796215?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:27","pubTimestamp":1788172079,"startTime":"0","endTime":"0","summary":"2026年8月31日，欧康维视生物-B发布自愿性公告称，其自研用于治疗中至重度干眼症的同类首创新药OT-202在中国开展的III期临床试验已完成首例患者入组。首例患者入组被视为该项目在中国临床开发的重要里程碑。\\n\\n临床进展方面：\\n1. OT-202的I期临床试验于2023年2月顺利完成，结果显示在健康成人受试者中具有良好的安全性和耐受性。\\n2. II期临床试验自2023年2月启动，设计为随机、双盲、安慰剂对照研究，共在中国完成213名患者入组，并于2023年11月结束。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074148","title":"欧康维视生物-B(01477)：OT-202 III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074148","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663074148?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:26","pubTimestamp":1788171975,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，用于治疗干眼症的 OT-202于中国进行的III期临床试验已完成首例患者入组。首例患者成功入组标志着OT-202在中国临床开发的一项重要里程碑，并体现集团为干眼症患者推进创新疗法的承诺。OT-202的II期临床试验，已于2023年11月于中国完成合共213名患者的II期临床试验入组。OT-202的II期临床试验结果已在国际顶尖眼科期刊《Ophthalmology》发表。2024年3月，OT-202的II期临床试验达到其主要终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","PSYK","BK1191","BMED","IBBQ","BK1574","MDTX","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663023533","title":"【新股IPO】邦顺制药向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2663023533","media":"金吾财讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663023533?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:43","pubTimestamp":1788136993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所8月30日披露，邦顺制药向港交所主板提交上市申请，中信建投国际为独家保荐人。财务方面，公司于2024至2025年以及2026年上半年，分别录的亏损8844.4万元、2.99亿元以及8015.5万元。股东层面，截至最后实际可行日期，李邦良通过杭州万裕和、杭州三睿和杭州六因泰持有公司约31.25%的投票权。","market":"sg","thumbnail":"https://static.szfiu.com/news/20220324/ZDg5MGY3YjA4MWNiNDkyZjgyMTczYjhiYWU0ZDI5OWEyNTc1MTQyMDQxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/ZDg5MGY3YjA4MWNiNDkyZjgyMTczYjhiYWU0ZDI5OWEyNTc1MTQyMDQxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRHC","BK1574","01477","KCE","HEXmain","REDS","BK1191","IPOS","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663040910","title":"新股消息 | 邦顺制药二次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2663040910","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663040910?lang=zh_cn&edition=full","pubTime":"2026-08-31 06:57","pubTimestamp":1788130620,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663442710","title":"邦顺制药冲刺港股：年亏3亿 李邦良控制31%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2663442710","media":"雷递网","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663442710?lang=zh_cn&edition=full","pubTime":"2026-08-30 22:30","pubTimestamp":1788100218,"startTime":"0","endTime":"0","summary":"杭州邦顺制药股份有限公司（简称：“邦顺制药”）日前更新招股书，准备在港交所上市。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260830/6392372580177336339063505.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260830/6392372580177336339063505.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34989/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4588","VXUS","01477","BK1191","KCAI","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663415150","title":"歌礼制药-B(01672)：每日一次口服小分子GLP-1受体激动剂ASC30用于长期体重管理的全球III期临床项目完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2663415150","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663415150?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:08","pubTimestamp":1788084524,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，ASC30用于长期体重管理的全球III期临床项目已完成首例受试者给药。ASC30是一款歌礼专有的、正在临床研究中的每日一次口服小分子胰高血糖素样肽-1受体激动剂，开发用于长期体重管理和糖尿病治疗。歌礼预计将于2028年第三季度公布AURORA III期临床项目的顶线数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","BK1191","BK1161","01477","JDOC","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663046742","title":"深度｜AI制药进入验证期：百万高薪人才难觅，吃到红利的第一波企业出现了","url":"https://stock-news.laohu8.com/highlight/detail?id=2663046742","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663046742?lang=zh_cn&edition=full","pubTime":"2026-08-30 15:27","pubTimestamp":1788074879,"startTime":"0","endTime":"0","summary":"在近期药企的财报交流会上，AI制药话题密集被提及。翰雨医药咨询（上海）有限公司Healthview合伙人李思春对AI制药有着更直观感受，因为行业的景气度，写在了招聘启事里。作为医药猎头，他服务的客户抛出的AI制药岗位需求增多，尤其是从去年到现在，这种现象更加明显，符合条件的人才并不好招，合适的候选人也容易被截胡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608303859386484.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608303859386484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CHAT","01477","BK1191","ARTY","BK1574","QTOC","VTHR","AGIX","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663409206","title":"欧康维视生物-B(01477.HK)发布中期业绩，经调整亏损净额5752.3万元 同比减少46.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663409206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663409206?lang=zh_cn&edition=full","pubTime":"2026-08-29 00:02","pubTimestamp":1787932956,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663061092","title":"欧康维视生物-B(01477)发布中期业绩，经调整亏损净额5752.3万元 同比减少46.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663061092","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663061092?lang=zh_cn&edition=full","pubTime":"2026-08-29 00:02","pubTimestamp":1787932956,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B(01477)发布截至2026年6月30日止6个月中期业绩，该集团取得收益4.24亿元，同比增加44.1%;经调整亏损净额5752.3万元，同比减少46.74%;每股亏损0.12元。公告称，收益大幅增加主要是由于销售眼科产品(包括优施莹®、适利达®、适利加®、爱赛平®及于Alcon交易项下自Alcon收购及授权引进的产品)产生的收入大幅增加;及以销售为基础的特许权使用费收入显著增加，主要由博优景®的成功商业化所驱动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198202086","title":"欧康维视生物-B（01477）调整资金用途　1.03亿元IPO余款及1,937万港元配售款转投营运资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1198202086","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198202086?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:22","pubTimestamp":1787926945,"startTime":"0","endTime":"0","summary":"8月28日，欧康维视生物-B公告称，董事会已决议调整部分募集资金用途，并将未动用的首次公开发售及配售所得款项合计约1.22亿港元重新分配至“营运资金及其他一般企业用途”，以匹配公司当前业务发展需求。截至2026年6月30日，已使用7.62亿元，占97.5%；尚余19.37百万港元未动用。董事会称，此次资金用途调整不会对现有业务造成重大不利影响，符合公司及股东整体利益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148920071","title":"欧康维视生物-B2026年上半年营收4.24亿元，净利润-0.58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148920071","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148920071?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:16","pubTimestamp":1787926578,"startTime":"0","endTime":"0","summary":"2026年上半年，欧康维视生物-B实现营收人民币4.24亿元，同比增长44.1%。同期经调整净利润为-0.58亿元，与去年同期相比亏损收窄46.7%。销售及营销费用约1.60亿元，占总营收的37.7%；管理费用约0.91亿元，占总营收的21.6%。报告期内，经调整EBITDA约0.23亿元，上年同期为-0.40亿元。报告期内，眼科产品仍是主要收入来源，销售收入约3.77亿元，较去年同期的2.85亿元增加约0.92亿元；销售相关的特许权使用费收入约0.44亿元，较去年同期的约0.02亿元大幅增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"欧康维视生物-B2026年上半年营收4.24亿元，净利润-0.58亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662622067","title":"长春高新最新公告：全资子公司凯美斯制药获新发集团不超4亿元股权投资意向","url":"https://stock-news.laohu8.com/highlight/detail?id=2662622067","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662622067?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:24","pubTimestamp":1787916245,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称，公司全资子公司凯美斯制药与间接控股股东新发集团签署《投资意向与合作框架协议》，新发集团计划通过资本运作等方式对凯美斯制药进行总额不超过4亿元的股权投资，分三个阶段推进，首期投资不超过3500万元，用于启动生产。本次交易构成关联交易，已获董事会审议通过，无需提交股东会审议。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800045261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK1574","000661","BK0239","BK0075","BK0046","01477","BK0188","BK1191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662054960","title":"直击业绩会 | 上市后首份半年报扭亏为盈，英硅智能管理层回应AI制药商业化可持续性","url":"https://stock-news.laohu8.com/highlight/detail?id=2662054960","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662054960?lang=zh_cn&edition=full","pubTime":"2026-08-28 14:40","pubTimestamp":1787899251,"startTime":"0","endTime":"0","summary":"8月27日，港股AI制药企业英硅智能（HK03696）发布上市后首份半年报：2026年上半年营收1.06亿美元，同比增长287.2%，实现净利润3553.7万美元，结束此前的亏损状态，经营现金流转正，截至6月末现金及投资组合合计5.85亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608283858062129.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608283858062129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AGIX","CHAT","BK1574","ARTY","AIPO","BK1191","QTOC","VTHR","01477","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662590051","title":"AI制药公司业绩会| 无论AI在研发中表现多亮眼，BD是硬指标，“成药”才是终极答案","url":"https://stock-news.laohu8.com/highlight/detail?id=2662590051","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662590051?lang=zh_cn&edition=full","pubTime":"2026-08-28 14:16","pubTimestamp":1787897784,"startTime":"0","endTime":"0","summary":"与此同时，行业共识逐渐凝聚，多位AI制药公司高管和行业人士向蓝鲸新闻表示，无论AI在早期研发中表现多亮眼，最终能否真正成药，才是检验AI制药价值的“DeepSeek时刻”。而对此，英硅智能联席首席执行官兼首席科学官任峰表示，AI制药的成功率目前尚无法量化，因为尚未有AI独立研发的药物完成III期临床并获批上市，缺乏统计样本。这是AI在临床阶段的终极","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787897739268930221","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","QTOC","AGIX","ARTY","AIPO","VTHR","01477","BK1191","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662583760","title":"AI制药迈向智能化自主验证新时代，科创医药ETF华夏（588130）跟踪指数盘中震荡整理","url":"https://stock-news.laohu8.com/highlight/detail?id=2662583760","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662583760?lang=zh_cn&edition=full","pubTime":"2026-08-28 10:30","pubTimestamp":1787884218,"startTime":"0","endTime":"0","summary":"科创医药板块分化，截至10:18，科创医药ETF华夏跟踪的上证科创板生物医药指数下跌0.79%，其成分股南微医学上涨2.53%，热景生物上涨1.82%，禾元生物-U上涨1.41%，天智航-U上涨1.29%。浙商证券研报指出，AI制药行业正从科学家决策转向智能化自主验证，平台价值在提升。科创医药ETF华夏提供了低门槛一键布局科创医药板块的便捷工具，跟踪上证科创板生物医药指数，科创板涨跌幅限制20%提供高弹性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026082800020223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","588130","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662030926","title":"仲景宛西制药向西藏吉隆灾区捐赠100万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662030926","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662030926?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:42","pubTimestamp":1787881320,"startTime":"0","endTime":"0","summary":"（来源：中国食品药品网）8月26日10时30分许，因尼泊尔一侧发生泥石流灾害，造成西藏日喀则市吉隆县吉隆口岸重大人员伤亡、失联。山河虽远，大爱相连；医圣仁心，千里驰援。秉承仲景济世救人、博施济众的医道初心，仲景宛西制药闻令而动，第一时间通过中国光彩基金会，向西藏吉隆泥石流灾区捐赠100万元善款，专项用于灾区抢险救援、群众临时安置与民生救助，以赤诚之力守护受灾群众，助力灾区渡过难关。仲景宛西制药将持续紧盯灾区救援与灾后重建，始终与吉隆各族人民守望相助，共克时艰，把中原企业的责任与温情，跨越山海送到雪域高原。《中国医药报》社版权所有，未经许可不得转载使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-28/doc-inipvrtx8927809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662793303","title":"退市不影响索赔！普利制药（300630）投资者索赔再提交法院立案","url":"https://stock-news.laohu8.com/highlight/detail?id=2662793303","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662793303?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:15","pubTimestamp":1787728500,"startTime":"0","endTime":"0","summary":"经查明，2021年至2022年，普利制药通过虚构成品药和原料药销售业务的方式，虚假确认药品销售收入和利润。普利制药披露的2021年年报、2022年年报存在虚假记载。专门从事股票索赔法律事务的上海久诚律师事务所主任许峰律师认为，在2022年4月26日到2024年4月17日之间买入普利制药股票，并且在2024年4月17日后卖出或继续持有股票的投资者，目前还可发起索赔。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2026-08-26/doc-iniprqcu2313649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK1574","01477","300630","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662762420","title":"新加坡7月电子产品产出同比增长11.2%，七月制药产出同比下降14.3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662762420","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662762420?lang=zh_cn&edition=full","pubTime":"2026-08-26 13:01","pubTimestamp":1787720468,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662691765","title":"诺华制药(NVS.US)重磅核药在华获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2662691765","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662691765?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:44","pubTimestamp":1787705088,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月25日，诺华制药宣布镥[177Lu]特昔维匹肽在华获批新适应症，用于联合雄激素受体通路抑制剂治疗前列腺特异性膜抗原阳性转移性激素敏感性前列腺癌患者。这是该药物在国内获批的第三项适应症，目前其可用于所有阶段的PSMA+转移性前列腺癌患者——从mHSPC到转移性去势抵抗性前列腺癌、覆盖化疗前至化疗后多个关键治疗阶段。此外，诺华近日也在国内递交了该药物的地产化生产申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0208291251.USD","LU0070302665.USD","IE00BJT1NW94.SGD","BK4007","BK4585","IE0002141913.USD","BK1191","NVS","BK1574","BK4532","IE00BFTCPJ56.SGD","BK4588","IE00B2B36J28.USD","IE0009355771.USD","LU0211331839.USD","IE00B4R5TH58.HKD","LU0320765489.SGD","01477","IE00BJJMRZ35.SGD","PPH","MEDX","BK4578"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0474},{"period":"3month","weight":-0.1452},{"period":"6month","weight":-0.2971},{"period":"1year","weight":-0.4085},{"period":"ytd","weight":-0.2838}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":-0.0086},{"period":"3month","weight":0.016},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.0234},{"period":"ytd","weight":-0.0018}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.087204},{"month":6,"riseRate":0.666667,"avgChangeRate":0.062947},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003589},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.048846},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}